1. Home
  2. SWVL vs CVKD Comparison

SWVL vs CVKD Comparison

Compare SWVL & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Swvl Holdings Corp

SWVL

Swvl Holdings Corp

HOLD

Current Price

$1.60

Market Cap

15.6M

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$5.10

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWVL
CVKD
Founded
2017
2022
Country
United Arab Emirates
United States
Employees
284
N/A
Industry
Business Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
13.8M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
SWVL
CVKD
Price
$1.60
$5.10
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
26.1K
66.1K
Earning Date
04-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$4.21
52 Week High
$4.99
$15.99

Technical Indicators

Market Signals
Indicator
SWVL
CVKD
Relative Strength Index (RSI) 42.42 42.02
Support Level $1.33 $4.91
Resistance Level $1.92 $6.09
Average True Range (ATR) 0.15 0.74
MACD -0.04 -0.09
Stochastic Oscillator 3.84 3.56

Price Performance

Historical Comparison
SWVL
CVKD

About SWVL Swvl Holdings Corp

Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: